The active ingredient in Wegovy (for weight management), Ozempic (for type 2 diabetes), and Rybelsus (an oral diabetes pill). It's a once-weekly injectable GLP-1 receptor agonist (the oral forms differ), and it has the most extensive long-term outcomes evidence in the class, including a completed cardiovascular trial. "Compounded semaglutide" refers to non-FDA-approved copies, which are a separate safety question.
Related terms: Wegovy · Ozempic · Rybelsus · Tirzepatide · Compounded medication
See also: Wegovy vs. Zepbound